Personal information

Other IDs

Loop profile: 928340

Activities

Collapse all

Works (29)

Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol

PLOS ONE
2023-11-27 | Journal article
DOI: 10.1371/journal.pone.0294147
Contributors: Anouk W. M. A. Schaeffers; Antonino Maniaci; Lot A. Devriese; Carla H. van Gils; Jan Willem Dankbaar; Jens Voortman; Jan Paul de Boer; Marije Slingerland; Mathijs P. Hendriks; Ernst J. Smid et al.
Source: check_circle
Crossref

Data from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6530805.v1
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Data from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6530805
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 1 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482048.v1
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 1 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482048
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 2 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482045
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 2 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482045.v1
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 3 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482042.v1
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 3 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482042
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 4 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482036
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 4 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482036.v1
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 5 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482033
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 5 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482033.v1
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 6 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482030.v1
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 6 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482030
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 7 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482027.v1
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 7 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482027
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 8 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482024.v1
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 8 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482024
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 9 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482021.v1
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure 9 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482021
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure legends from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482018.v1
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary figure legends from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482018
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary table 1 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482015
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary table 1 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482015.v1
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary table 2 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482009
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Supplementary table 2 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482009.v1
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

More than a Bubble: Extracellular Vesicle microRNAs in Head and Neck Squamous Cell Carcinoma

Cancers
2022-02-24 | Journal article
DOI: 10.3390/cancers14051160
Contributors: Wittaya Panvongsa; D. Michiel Pegtel; Jens Voortman
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells

Clinical Cancer Research
2022-01-01 | Journal article
DOI: 10.1158/1078-0432.CCR-20-3319
Contributors: Maud Rijnders; Hayri E. Balcioglu; Debbie G.J. Robbrecht; Astrid A.M. Oostvogels; Rebecca Wijers; Maureen J.B. Aarts; Paul Hamberg; Geert J.L.H. van Leenders; J. Alberto Nakauma-González; Jens Voortman et al.
Source: check_circle
Crossref

Peer review (2 reviews for 2 publications/grants)

Review activity for Journal for immunotherapy of cancer. (1)
Review activity for The lancet. (1)
How many people are using ORCID?